Temporary rapid ventricular pacing (TRVP) is required during transcatheter aortic valve implantation (TAVI) in order to reduce cardiac output and to facilitate balloon aortic valvuloplasty, prosthesis deployment, and post-deployment balloon dilation. The two most frequently used TRVP techniques are right endocardial (RE)-TRVP and retrograde left endocardial temporary rapid ventricular pacing (RLE)-TRVP. The first one could be responsible for cardiac tamponade, one of the most serious procedural complications during TAVI, while the second one could often be unsuccessful.
View Article and Find Full Text PDFAtrial fibrillation (AF) is the most common arrhythmia worldwide. Thromboembolism from the left atrial appendage (LAA) is the most feared complication in patients with AF. The cornerstone for the management of AF is oral anticoagulation to reduce the incidence of cardioembolic stroke.
View Article and Find Full Text PDFBackground: In recent years, direct-acting oral anticoagulants (DOACs) have entered clinical practice for stroke prevention in non-valvular atrial fibrillation or prevention and treatment of venous thromboembolism. However, remaining uncertainty regarding DOAC use in some clinical scenarios commonly encountered in the real world has not been fully explored in clinical trials.
Methods: We report on use of a Delphi consensus process on DOAC use in non-valvular atrial fibrillation patients.
A 66-year-old patient with a recent history of chest pain was submitted to exercise test. The rest electrocardiogram was normal, but during effort, a striking U-wave inversion in the chest leads occurred, not associated with any ST-segment change. Coronary angiogram demonstrated a severe proximal narrowing of the left anterior descending coronary artery.
View Article and Find Full Text PDF